Abstract. In esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) has a curative potential even in cases of locally advanced carcinoma. However, only about half of the patients benefit from CRT, and an accurate prediction of sensitivity to CRT is eagerly awaited. Using microarrays, we analyzed gene-expression patterns of pretreatment biopsy specimens from 33 patients with CRT alone including longterm survivors, more than 3 years (14 cases) and short-term survivors, less than 1 year (11 cases). The expression patterns of about 12,600 genes were used to identify genes correlated with survival terms. Fifty-seven genes correlating with shortterm survival and 120 genes with long-term survival were identified. The genes involved in the immune response were characteristically upregulated in the long-term survivors, and an immunohistochemical staining confirmed an increased CD8-positive T cell number in the long-term survivors over that in the short-term survivors. In the short-term survivors, on the other hand, increased expression of the genes involved in drug resistance was observed. Our gene list should contribute to the elucidation of the mechanisms of CRT response and contains useful markers for predicting the prognosis of individual ESCC patients treated with CRT alone.
Introduction
Esophageal cancer in East Asian countries including Japan and China, and in some parts of Europe consists mainly of squamous cell carcinomas located mostly in the thoracic esophagus, while adenocarcinoma in the distal part of the esophagus has increasingly become the major pathological type found in Europe and North America. Overall, esophageal squamous cell carcinoma (ESCC) is the sixth most frequent cancer in the world, and is a highly virulent disease. Although surgery is the standard therapy for locally confined ESCC, results of surgery alone remain poor, with 5-year survival rates of 6-24% in Western countries (1) . Recent improvement in surgical results following radical node dissection has been reported at some Japanese institutions, with 5-year survival rates of 31-55% (2, 3) . In a Japanese prospective randomized study that compared surgery alone with surgery followed by adjuvant chemotherapy, the group that received surgery with radical dissection alone showed a 5-year survival rate of 45%, although the study did not show a survival advantage over treatment with adjuvant chemotherapy (4) . The success of radical surgery led many Japanese surgeons to extend the indications of surgery to locally advanced carcinoma. On the other hand, a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has become a standard world regimen, not only because of its clinical outcome, but also because of the synergism between the two agents and their radiosensitizing effects (5) (6) (7) . Recent studies clearly indicated that definitive chemoradiotherapy (CRT) seemed to have a curative potential even in cases of locally advanced carcinoma (8) , although the treatment may be associated with significant toxicity (9) . The reported 5-year survival rate is 27% or 29% (9, 10) . Despite recent progress in the molecular genetics of ESCC, little is known about the mechanisms of sensitivity to CRT, and a prediction of the outcome of CRT by clinicopathological terms still remains very difficult. We conducted gene expression profiling using an oligonucleotide microarray of pretreatment biopsy samples from 33 ESCC patients treated with CRT alone. The purpose of the study was to explore the underlying mechanisms of CRT responses and to contribute to the development of the markers, which aid to select the best therapeutic modality prior to the initiation of therapy.
Materials and methods

RNA isolation from biopsy specimens.
Patients received protracted infusion of 5-FU 400 mg/m 2 /24 h on days 1-5 and 8-12, 2-h infusion of CDDP 40 mg/m 2 on days 1 and 8, and concurrent radiation therapy at a dose of 30 Gy in 15 fractions over 3 weeks. Filgrastim was prophylactically administered to all patients. This schedule was repeated twice every 5 weeks, for a total radiation dose of 60 Gy, followed by two courses of 5-FU (800 mg/m 2 /24 h for 5 days) and CDDP (80 mg/m 2 on day 1). Biopsy samples, which were obtained from patients before CRT, were immediately frozen at -80˚C until use. The samples were homogenized in Isogen lysis buffer (Nippon Gene Co., Ltd., Toyama, Japan) at room temperature, extracted with chloroform, and precipitated with 20 μg glycogen in isopropanol. The RNA pellet was resuspended in RNase-free water, and treated with RNase-free DNase I in the presence of RNase inhibitor followed by phenol extraction and precipitation in isopropanol. The pellet was resuspended in 15 μl of RNasefree water; one-third of the total RNA from each sample was used for quality analysis of RNA by RNA LabChip (Caliper Technologies Corp., CA), and an appropriate amount from the remaining two-thirds was used for oligonucleotide microarray analysis. This study with biopsy specimens was approved by our institutional review boards.
Microarray analysis. We used human U95A oligonucleotide probe arrays (Affymetrix, Santa Clara, CA) for analysis of mRNA expression levels corresponding to 12,600 transcripts. The procedures were conducted according to the supplier protocols, and are thus described briefly. Each 5 μg of total RNA was used to generate a cRNA probe. Ten microgram of fragmented cRNA was hybridized to the microarrays in 200 μl of a hybridization cocktail at 37˚C for 16 h in a rotisserie oven set at 60 rpm. The arrays were then washed with a low stringent wash buffer (6X SSPE) at 25˚C, followed by stringent wash buffer [100 mM MES (pH 6.7), 0.1 M NaCl, and 0.01% Tween-20] at 50˚C, stained with streptavidin phycoerythrin (Molecular Probes), washed again with 6X SSPE, stained with biotinylated anti-streptavidin IgG, followed by a second staining with streptavidin phycoerythrin and a third wash with 6X SSPE. The arrays were scanned using a GeneArray scanner (Affymetrix) at 3-μm resolution, and quantitatively the canned image analyzed with computer software Microarray Suite 4.0 (Affymetrix). For normalization of the data to compare mRNA expression levels among the samples, we unified 1000 as an average of AD scores corresponding to signal intensities of all probe sets in each sample. We selected genes whose expression levels were higher than an average of signal intensity in one group (14 long-term survivors or 11 short-term survivors) plus its standard deviation (SD) in more than 60% of another group. The two-dimensional hierarchical clustering analysis of the 177 selected genes differentially expressed in longand short-term survivors was performed by the Cluster and Treeview programs (11) .
RNA slot blot analysis. To verify differences in expression indicated by microarray analysis, we performed slot blot analysis of cRNAs produced from total RNA extracted from 14 long-term survivors and 12 short-term survivors. A SuperScript Choice System (Invitrogen Corp., CA) was used for cDNA synthesis prior to generating cRNA. A MEGAscript in vitro Transcription Kit (Ambion Inc., TX) was used for cRNA production by in vitro transcription using T7 RNA polymerase. Each 0.5 μg cRNA was denatured and blotted to a NitroPlus membrane (Micron Separations, Inc.). The filter was hybridized with radiolabeled probes. Hybridization was carried out in 50% formamide, 5X standard saline citrate (SSC) (1X standard saline citrate = 0.15 M NaCl, 0.015 M sodium citrate), 5X Denhardt's solution, 5 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 10% dextran sulfate, and 100 μg/ml denatured salmon sperm DNA at 42˚C for 16 h. The filter was washed twice in 0.1X SSC and 0.1% SDS at room temperature for 10 min each and then washed at 65˚C for 30 min, and exposed to Kodak XAR film at -80˚C.
Immunohistochemical analysis. Biopsy specimens were embedded in paraffin, sectioned, and treated with phosphatebuffered saline (PBS). The specimen was then treated with a blocking reagent containing 10% goat serum and incubated with an anti-CD8 antibody in PBS also containing 3% goat serum. After incubation with the secondary antibody, a streptavidin-peroxidase solution was applied to the specimen followed by a development solution containing diaminobenzidine.
Results
Classification of ESCC patients who received CRT alone and microarray analysis.
The clinicopathological characteristics of 33 esophageal carcinoma patients who received CRT alone are summarized in Table I . All cases were diagnosed as squamous cell carcinoma, and all patients were treated according to the same protocol as described in Materials and methods. Twenty-five of the 33 patients were classified into two groups on the basis of the duration of survival: long-term survivors, more than 3 years (14 cases, A-1-1 to A-1-14); short-term survivors, less than 1 year (11 cases, D-1-1 to D-1-11). The two groups showed no significant differences with respect to clinicopathological features. Of the remaining 8 patients, 6 (A-2-1 to A-2-4, D-2-1, and D-2-3) survived for 2-3 years until the end of the follow-up period, and 2 patients (D-2-2 and D-2-4) survived for 1-2 years. Approximately 10-30 μg of total RNA was isolated from each biopsy sample of these 33 ESCC patients, and all RNA samples were confirmed to be of good quality by visualization of ribosomal RNAs using the capillary electrophoresis method as described in Materials and methods and considered sufficient for microarray analysis. The 33 RNA samples were converted to cRNA, labeled by biotin and hybridized to Affymetrix Human Genome U95Av2 Array according to the protocol recommended by the manufacturer (Affymetrix, CA, USA). The array analyzed mRNA expression levels corresponding to 12,600 transcripts. First, we conducted an unsupervised clustering analysis using the 316 genes expressed (i.e., gave 'Presence' call by data analysis) in all the 33 samples. Three patient clusters appeared (Fig. 1) . Cluster 1 (7 cases) consisted of 5 long-term survivors (A-1-1, A-1-7, A-1-9, A-1-11, and A-1-13), and 6 of the 7 cases (86%) in this cluster survived for more than 2 years. Cluster 2 (15 cases) consisted of 9 short-term survivors (D-1-1 to D-1-5, and D-1-7 to D-1-10), and 73% of the cases of this cluster (11 of 15) survived for less than 2 years. Cluster 3 (11 cases) consisted of 6 long-term survivors (A-1-2, A-1-5, A-1-6, A-1-10, A-1-11, and A-1-14), and 10 of the 11 cases (91%) of this cluster survived for more than 2 years. In summary, 11 (79%) of the 14 long-term survivors (A-1-1 to A-1-14) or 16 (80%) of the 20 cases that survived for more than 2 years were grouped into clusters 1 and 3, whereas cluster 2 was characterized by a poorer prognosis, gathering 9 (82%) of the 11 short-term survivors (D-1-1 to D-1-11) or 10 (77%) of 13 cases that survived for less than 2 years. These unsupervised data on expression profiling suggested the presence of distinct subclasses within the 33 patient groups, and the subclasses may be associated with the survival term.
To compile a gene list for prognostic marker candidates for CRT, we selected genes by comparing expression levels between the two groups, 14 long-term survivors and 11 shortterm survivors. A gene was selected if more than 60% of the samples in one group expressed the gene at a higher level than an average of signal intensity plus its standard deviation (SD) in the other group. By this procedure, 57 genes associated with short-term survival and 120 genes with long-term survival were identified (Table II) . To investigate whether the subclass exists among long-term survivors or short-term survivors, we Table I . Clinical outcome and disease stage of 33 patients.
a A CR was defined as the complete disappearance of all measurable and assessable disease for a minimum of 4-weeks.
b Disease-free survival (days).
carried out a two-dimensional hierarchical clustering analysis of the 177 selected genes. A dendrogram of the clustering analysis was generated, and is shown in Fig. 2 . Two patient clusters (vertical bar) and three gene clusters (horizontal bar) were recognized. One of the two patient clusters consisted of 10 of 11 short-term survivors, and the other patient cluster included all of the 14 long-term survivors. Only one case (D-1-11) was found in an inappropriate cluster. Among the gene clusters, the 11 short-term survivors appear to compose a single gene cluster (A in Fig. 2 ), whereas two major gene clusters, B and C, exist for the 14 long-term survivors.
Genes differentially expressed between long-and short-term survivors.
We next analyzed the known functional annotations of 177 genes identified as differentially expressed genes between the long-and short-term survivors. More than 20 out of 120 genes over-expressed in the long-term survivors were found to have some functions in the immune response (Table II) . (11) . The results showed a significant association between the expression profile and the survival term. The long-term survivors (red), the short-term survivors (blue). Table II . Over-expressed genes in long-or short-term survivors. Long-term  survivor  1  U19142  GAGE1  2  L76191  IRAK1  3  X53777  RPL17  4  AF023612  DIM1  5  M96860  DPP6  6  AF031416  IKBKB  7  Z48482  MMP15  8  S61953  ERBB3  9  Y18448  BSN  10  W26628  MRPL9  11  M24194  GNB2L1  12  D63478  NICE-4  13  AF054187  NACA  14  U84570  C21orf2  15  J03592  SLC25A6  16  U87954  PA2G4  17  Z48481  MMP14  18  AB016902  MLLT4  19  AI381790  APM2  20  M24194  GNB2L1  21  M62982  ALOX12  22  Y00764  UQCRH  23  X78710  MTF1  24  H16917  KIAA0563  25  AB028959  KIAA1036  26  M86667  NAP1L1  27  M32334  ICAM2  28  L05148  ZAP70  29  M31767  MGMT  30  M54914  FSHB  31  M60483  PPP2CA  32  M90356  BTF3L3  33  X96969  SLC14A2  34  Z50853  CLPP  35  X75252  PBP  36  AB029036  TRIM33  37  AB014596  FBXW1B  38  M58458  RPS4X  39  Z25749  RPS7  40  AF070638  CGI-57  41  Z46973  PIK3C3  42  L33842  IMPDH2  43  J04132  CD3Z  44  S72869  D10S170  45  M31315  F12  46  U70451  MYD88  47  L19185  PRDX2  48  D11466  PIGA  49  D89667  MM-1  50  D21089  XPC  51  U19144  GAGE3  52  AL050135  RFX5  53  AB018344  DDX46  54  AF052155  SEC13L1  55  U19145  GAGE5  56  X15940  RPL31  57  AF039555  VSNL1  58  S79522  RPS27A  59  AC004523  CYP4F12  60  X78926  ZNF268 Table II . Continued.
-------------------------------------------------No. GenBank Gene symbol -------------------------------------------------
- Long-term  survivor  61  U91329  KIF1C  62  AB002332  CLOCK  63  AF054174  H2AFY  64  Z11692  EEF2  65  AA846749  APOM  66  D83702  CRY1  67  U22526  LSS  68  AB007960  SH3GLB1  69  J02625  CYP2E1  70  AL080119  PAI-RBP1  71  M24398  PTMS  72  AI816034  NOLA2  73  M32313  SRD5A1  74  L18960  EIF1A  75  D87002  IGL  76  S76992  VAV2  77  M95678  PLCB2  78  X69391  RPL6  79  M86546  PBX1  80  AB002533  KPNA4  81  M58378  SYN1  82  X53505  RPS12  83  Y09445  TBX5  84  AF112472  CAMK2B  85  AF025654  RNGTT  86  AB007447  FLN29  87  AF006621  SLC30A9  88  U35139  NDN  89  M23323  CD3E  90  U79259  DJ159A19.3  91  X04828  GNAI2  92  Z22865  DPT  93  AF037195  RGS14  94  W72733  KIAA1536  95  AL096744  REV3L  96  AB005047  SH3BP5  97  AB007896  KIAA0436  98  L24564  RRAD  99  W26677  FLJ35827  100  Z22555  SCARB1  101  M64174  JAK1  102  U88629  ELL2  103  S77812  FLT1  104  U26455  ATM  105  X72631  NR1D1  106  M83088  PGM1  107  M28393  PRF1  108  AF010242  SYNPO  109  M81141  HLA-DQB1  110  M17016  GZMB  111  U69645  ZNF32  112  X54871  RAB5B  113  U15552  HSU15552  114  AB014597  ANKRD17  115  M64322  PTPN7  116  AB018333  SASH1  117  M98539  PTGDS  118  AI526079  RPL22  119  AF062341  CTNND1  120  AF030234  SFRS2IP   Table II . Continued. -term  survivor  1  AF030428  T1A-2  2  Z80782  HIST1H2BI  3  AF035287  SDFR1  4  Y08614  XPO1  5  AL049944  DKFZP564G2022  6  Z83738  HIST1H2BM  7  U35451  CBX1  8  AL050089  BAZ1A  9  AF009615  ADAM10  10  X59892  WARS  11  U51920  SRP54  12  D13629  KTN1  13  Z80779  HIST1H2BF  14  AB023187  KIAA0970  15  U53204  PLEC1  16  D38551  RAD21  17  AI888084  GPR107  18  X63679  TRAM1  19  D83485  GRP58  20  AL120559  ARPP-19  21  U29332  FHL2  22  AF013759  CALU  23  X82103  COPB  24  AA142964  LOC285148  25  AL049851  CARD10  26  U76421  ADARB1  27  AI365215  RRAS2  28  AF084523  CREG  29  M35878  IGFBP3  30  AF085692  ABCC3  31  D38521  PSME4  32  L02426  PSMC1  33  U81006  TM9SF2  34  AJ223352  HIST1H2BK  35  AF043324  NMT1  36  AB014562  PHF2  37  AA176780  TRIM44  38  AJ010901  MUC4  39  L04282  ZNF148  40  M57730  EFNA1  41  AF038844  DUSP14  42  AB014529  AKAP11  43  J03060  GBA  44  M13194  ERCC1  45  X55885  KDELR1  46  AF006010  DD5  47  AF012072  EIF4G3  48  AB002357  KIF3B  49  L24123  NFE2L1  50  X76534  GPNMB  51  AF011468  STK6  52  X13466  APP  53  U28249  FXYD3  54  U49020  MEF2A  55  U82328  PDHX  56  AL022162  OCRL  57 AI018098 MGC15523  ------------------------------------------------- For example, GZMB/Granzyme B, Perforin1 and ICAM2 encoding crucial effectors for cytolysis by natural killer cells and cytotoxic T cells or for recruitment of those cells were found over-expressed in 14, 10, and 9 of the 14 long-term survivors, respectively. Similarly, of the 14 long-term survivors, upregulations were noted for GAGE1, 3 and 5 encoding tumor antigen mRNAs in 11, 12, and 10 patients, IRAK1, MyD88 and IKBKB encoding factors for IL-1 receptor-mediated NFκB activation in 11, 9, and 9 patients, VAV2 and ZAP70 encoding crucial effectors for T cell activation by APC-T cell interaction in 9 and 9 patients, and the MHC class II gene in 9 patients, respectively. These data suggest that cytotoxic T cell activation occurred preferentially in the long-term survivors. It is also noted that a vascular endothelial cell receptor gene FLT1 was over-expressed in 7 of the 14 longterm survivors.
------------------------------------------------No. GenBank Gene symbol -------------------------------------------------
In contrast, there was only a limited number of genes involved in T cell activation in the 11 short-term survivors. As shown in Table II , 57 genes associated with the shortterm survivors were identified. ABCC3/MRP3 and ERCC1 which are involved in drug resistance were found overexpressed in 9 and 8 of the 11 short-term survivors. Among the other over-expressed genes in the short-term survivors, BAZ1A and SRP54, which were located at chromosome 14q12-13, have been reported amplified in ESCCs (12) .
To verify the differences in expression indicated by microarray analysis, we performed slot blot analysis of cRNAs produced from total RNA extracted from 8 of the 14 long-term survivors and 8 of the 11 short-term survivors, whose RNAs were available in both microarray and slot blot analyses. Microarray data and the slot blot data of some of the above-mentioned genes are shown in Fig. 3 . By slot blot analysis, over-expression of GZMB, ICAM, GAGE1, IRAK1, and IKBKB was observed in the long-term survivors. In the short-term survivors, overexpression of ABCC3 and IGFBP3 was confirmed.
Comparison of the number of tumor infiltrating T-lymphocytes
between long-and short-term survivors. Next, using paraffinembedded tissues of 7 biopsy samples of the 14 long-term survivors and all of the 11 short-term survivors, which were available for immunohistochemistry, we compared the number of tumor infiltrating lymphocytes between the long-term survivors and the short-term survivors. As shown in Fig. 4 , the CD8-positive T cell numbers in a field (x200) in 7 longterm survivors were 50, 35, 21, 15, 7, 5 and 2, respectively, whereas those in 11 short-term survivors were 25, 3, 2, 2, 2, 2, 2, 0, 0, 0, and 0, respectively. The CD8-positive T cell number in the long-term survivors was significantly higher than that in the short-term survivors, although A-1-7 and D-1-10 were exceptions. However, D-1-10, the short-term survivor with 25 CD8-positive T cells in a field, showed no over-expression of any of the 14 above-mentioned genes for T cell activation, whereas the genes were over-expressed in all of the long-term survivors except A-1-7. These data suggested that the increased number of activated T cells in a tumor is significantly associated with a good prognosis for patients with ESCC treated by CRT.
Discussion
The clustering analysis on gene expression profiles (Fig. 2) together with the known functions of the genes selected as prognostic marker candidates (Table II) suggested that multiple factors are involved in the sensitivity and resistance to CRT in ESCC. The early studies in the basic radiation biology of tumor tissues, both in vitro and in vivo showed that well-oxygenated cells are radiosensitive (13) (14) (15) . Recently, it has been reported that microvessel density in laryngeal SCCs and ESCCs is a useful factor for predicting radiosensitivity (16, 17) . These vascularity-oxygenation-radio- Microarray data of the 7 genes (GZMB, ICAM, GAGE1, IRAK1, and IKBKB over-expressed in long-term survivors; ABCC3 and IGFBP3 over-expressed in short-term survivors) are plotted (upper). The cRNA slot blot data of the 7 genes in two sets of total RNAs extracted from 8 of the 14 long-term survivors (L) and 8 of the 11 short-term survivors (S), whose RNAs were available in both microarray and slot blot analyses (lower). Over-expression of GZMB, ICAM, GAGE1, IRAK1, and IKBKB was observed in the long-term survivors. In the short-term survivors, over-expression of ABCC3 and IGFBP3 was confirmed. sensitivity relationships seem to be supported also by our analysis, in which we noted over-expression of a tumor vessel marker gene FLT1 in the long-term survivors.
Second, it has been recognized that doses of radiation, lower than or equal to those that cause direct cytolysis, may alter the phenotype of target tissue by up-regulating gene products that may make tumor cells more susceptible to Tcell-mediated immune attack (18, 19) . Our present results (Fig. 4) suggest that the effect of CRT is correlated with the number of CD8-positive T cells in a tumor in each patient. Therefore, genes for T cell activation and for tumor vessel formation may become good markers for identifying potentially long-term survivors.
On the other hand, identification of poor-responders to CRT is also clinically important in the decision process for treatment modality. The genes which might be associated with the short-term survival include those for drug resistance or apoptosis resistance and some genes such as BAZ1A and SRP54 showing gene amplification in ESCC.
Establishment of a CRT response prediction algorithm requires ascertainment of another set of validation samples. However, our analysis suggests the feasibility of such class prediction, and the gene list may contribute to the understanding of the underlying molecular architecture of the heterogeneity of CRT responses and the selection of useful markers for predicting the prognosis of individual ESCC patients treated with CRT alone.
